Parkinson’s disease, a debilitating neurodegenerative disorder, affects millions worldwide, characterized by the loss of dopamine-producing neurons leading to motor dysfunction and a spectrum of non-motor symptoms. Despite decades of research, teasing apart the heterogeneous nature of PD has remained a foremost challenge. The dichotomous theory posits that some patients experience an initial pathological insult in the brain (Brain-First subtype), while in others, the disease process begins in the peripheral autonomic nervous system before ascending to the brain (Body-First subtype). This crucial differentiation could tailor early intervention strategies, but has been limited by a lack of definitive biomarkers to reliably classify patients.

This new study, appearing in the prestigious journal npj Parkinson’s Disease, leverages the well-established technique of dopamine transporter single-photon emission computed tomography (DAT-SPECT). DAT-SPECT is routinely employed to visualize striatal dopaminergic integrity, serving as a surrogate marker for neurodegeneration in PD. However, solely relying on conventional DAT-SPECT metrics has not been sufficient to disentangle the proposed Brain-First versus Body-First subtypes. The innovation arises by integrating radiomics, an emerging field that extracts a large number of quantitative features from medical images using advanced computational algorithms.

Radiomics can unveil subtle patterns and textures within images imperceptible to the human eye and standard metrics. By applying radiomics-enhanced analysis to DAT-SPECT brain scans, the research team identified distinguishing signatures correlated with the two PD subtypes. These signatures capture nuanced heterogeneity in tracer uptake distribution, asymmetry, and shape characteristics of the striatal dopaminergic deficit. Such imaging phenotypes open avenues to classify individual patients more precisely and understand the underlying pathological geography.

Importantly, the study recruited a rigorously phenotyped patient cohort, encompassing newly diagnosed PD individuals along the suggested Brain-First and Body-First trajectories. The researchers validated their radiomics-based classification model against conventional visual and semi-quantitative assessments, demonstrating superior performance in discriminating subtypes. This breakthrough underscores the potential of combining conventional nuclear imaging with high-dimensional radiomic feature extraction to enhance diagnostic granularity, paving the way for personalized medicine in Parkinson’s.

Delving into the methodology, raw DAT-SPECT images underwent meticulous preprocessing to standardize spatial and intensity parameters, ensuring robustness across multi-center datasets. From the processed images, over one hundred radiomic features were extracted encompassing first-order statistics, shape, texture, and intensity-based metrics. Advanced machine learning algorithms were employed to identify the most discriminative features, culminating in an optimized classifier that markedly separated Brain-First and Body-First phenotypes with statistical rigor.

The implications of these findings extend beyond diagnosis alone. Accurately identifying PD subtypes at early stages can inform prognosis, as the Brain-First and Body-First forms differ not only in initial symptomatology but also in progression rate, cognitive involvement, and response to therapies. For instance, Body-First patients frequently experience pronounced autonomic dysfunction and REM sleep behavior disorder, whereas Brain-First patients show earlier cognitive impairment. Tailored monitoring protocols and therapeutic regimens could therefore improve patient outcomes substantially.

Moreover, this work holds promise for unraveling the pathogenic mechanisms that have long eluded the scientific community. The ability to label patients according to their disease origin supports hypotheses about distinct spreading patterns of alpha-synuclein pathology, the hallmark protein aggregate driving PD. Brain-First cases may reflect central neurodegeneration originating within substantia nigra neurons, while Body-First forms could represent peripheral-to-central propagation. Mapping these pathways with imaging aids in targeting disease-modifying treatments to the site of earliest involvement.

The radiomics-enhanced DAT-SPECT approach also advances the field of biomarker research in neurodegeneration, exemplifying how machine learning and quantitative image analysis can overcome limitations of conventional interpretation. As large international consortia collect extensive multimodal imaging and clinical datasets, such integrative analytic techniques will accelerate biomarker discovery, validation, and clinical adoption, transforming the diagnostic landscape.

Despite its promise, the research team acknowledges remaining challenges before widespread clinical translation. Larger multicenter studies are necessary to confirm replicability and generalizability across diverse populations and imaging platforms. Longitudinal investigations will elucidate how imaging phenotypes evolve over disease course and whether they predict therapeutic responses. Additionally, incorporation of complementary modalities such as MRI and peripheral biomarkers could refine subtype stratification further.

Nonetheless, this study represents a seminal leap forward in differentiating PD subtypes through sophisticated imaging analytics. By harnessing the synergy of radiomics and DAT-SPECT, clinicians now possess a powerful tool to unmask the heterogeneity underlying Parkinson’s disease, bringing precision neurology within reach. As this paradigm expands, it could catalyze new avenues for early intervention, pathophysiological understanding, and ultimately, personalized care to improve lives guarded by this relentless disorder.

The researchers envision future integration of their radiomics-based classifier into routine nuclear medicine workflows. This would enable prompt subtype identification immediately after diagnostic imaging, facilitating tailored clinical decision-making. Combined with emerging disease-modifying agents and symptomatic therapies, personalized management strategies targeting Brain-First or Body-First subgroups could revolutionize standard PD care.

In conclusion, the study published by Palermo and colleagues signals an exciting juncture in Parkinson’s research, showcasing the power of cutting-edge image analysis to clarify a major unresolved question in the field. The capacity to discriminate Brain-First from Body-First PD using conventional and radiomics-enhanced DAT-SPECT images sets the stage for fundamentally improving diagnostic accuracy, patient stratification, and targeted treatment approaches. This paradigm shift illustrates how artificial intelligence and quantitative imaging can transform clinical neuroscience, offering renewed hope in the battle against Parkinson’s disease.

Subject of Research: Differentiation of Brain-First and Body-First Parkinson’s disease subtypes using dopamine transporter SPECT imaging and radiomics.

Article Title: Discriminating between proposed Brain-First and Body-First Parkinson’s disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis.

Article References:
Palermo, G., Aghakhanyan, G., Bellini, G. et al. Discriminating between proposed Brain-First and Body-First Parkinson’s disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis. npj Parkinsons Dis. 11, 328 (2025). https://doi.org/10.1038/s41531-025-01164-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-025-01164-z

Parkinson’s disease, a progressive neurodegenerative disorder characterized primarily by motor impairments such as tremors, rigidity, and bradykinesia, has long challenged clinicians with its heterogeneous presentation and unpredictable progression. Conventional imaging and clinical scales often fall short in predicting which individuals in the prodromal phase—those experiencing subtle, non-motor symptoms like hyposmia or REM sleep behavior disorder—will rapidly deteriorate. The innovative approach spearheaded by Xing, Lin, Li, and colleagues exploits advances in neuroimaging and fluid dynamics analysis, propelling predictive neurology into uncharted territory.

At the core of this investigation is the perivascular space (PVS), also known as Virchow-Robin spaces, which surround blood vessels as they penetrate the brain’s parenchyma. These spaces are instrumental in the glymphatic system, a recently elucidated network responsible for clearing interstitial solutes and metabolic byproducts from the central nervous system during sleep. The efficiency of solute clearance in the brain is crucial, as accumulation of misfolded proteins like alpha-synuclein is implicated in Parkinson’s pathology.

The researchers utilized advanced diffusion-weighted magnetic resonance imaging (DW-MRI) protocols optimized for quantifying fluid diffusivity within perivascular compartments. By meticulously mapping diffusivity changes, they uncovered a distinct pattern correlating with disease stage and severity. Subject cohorts included individuals with prodromal symptoms suggestive of Parkinson’s and patients in the earliest clinical stages of the disease, enabling a longitudinal perspective on disease evolution.

Crucially, the study demonstrated that increased diffusivity of perivascular space fluid precedes overt symptom manifestation and is a potent predictor of subsequent clinical deterioration. This suggests that disruption of perivascular clearance mechanisms may not merely accompany but actively contribute to neurodegeneration. The implications extend beyond diagnostics, hinting at novel therapeutic targets aimed at restoring or enhancing glymphatic function to slow or halt disease progression.

Biophysically, increased fluid diffusivity in PVS may reflect breakdown or dysfunction of the perivascular membrane structures, altered vascular pulsatility, or perturbations in cerebrospinal fluid dynamics. These alterations could facilitate the buildup of neurotoxic proteins and inflammatory mediators, creating a self-propagating cycle of neural injury. The findings align with emerging hypotheses situating vascular and clearance system dysfunction as central in neurodegenerative disease pathogenesis.

From a methodological perspective, the study represents a triumph in integrating advanced neuroimaging with computational fluid dynamics modeling. High-resolution DW-MRI allowed for non-invasive quantification of minute fluid movement signatures, while statistical analyses controlled for confounding factors such as age, comorbidities, and medication status. The robust correlation between perivascular fluid diffusivity and clinical metrics of decline strengthens confidence in the biomarker’s utility.

The potential clinical applications are vast. Early identification of high-risk individuals through PVS fluid diffusivity measurements could prioritize candidates for neuroprotective trials. Moreover, tracking diffusivity changes longitudinally offers an objective measure to evaluate response to emerging therapies targeting glymphatic function or alpha-synuclein aggregation. Translation into accessible clinical imaging protocols could revolutionize personalized medicine approaches for Parkinson’s disease.

This discovery also prompts renewed interest in the glymphatic system’s role in neurodegeneration more broadly. While traditionally overshadowed by neuronal and synaptic pathology, the clearance pathways constitute a critical frontier in neuroscientific research. Insights gained here may inform understanding of other disorders marked by proteinopathy and chronic inflammation, including Alzheimer’s disease, multiple system atrophy, and Lewy body dementia.

Despite the enthusiasm, the authors acknowledge limitations and emphasize the necessity for larger, multicenter studies to validate findings across diverse populations. The field awaits replication of these results and refinement of imaging techniques to standardize perivascular fluid diffusivity assessment. Furthermore, disentangling causality versus correlation remains a key challenge—does impaired clearance drive pathology, or does neurodegeneration disrupt the PVS environment?

Nevertheless, the research embodies an exciting paradigm shift. It underscores a systems-level appreciation of Parkinson’s disease pathophysiology, integrating vascular, immunological, and protein-clearance elements. Such holistic perspectives transcend reductionist neuron-centric views and hold promise for comprehensive disease-modifying strategies.

In conclusion, the identification of perivascular space fluid diffusivity as a predictive biomarker heralds a new dawn in Parkinson’s research. By bridging neuroimaging, fluid dynamics, and clinical neurology, Xing and colleagues have illuminated a novel facet of disease biology that may enable earlier diagnosis, better prognostication, and more targeted interventions. As the global burden of Parkinson’s disease mounts with aging populations, innovations like this are urgently needed to improve outcomes and quality of life for millions affected by this relentless disorder.

Subject of Research:
Assessment of perivascular space fluid diffusivity as a biomarker predicting clinical deterioration in prodromal and early-stage Parkinson’s disease.

Article Title:
Perivascular space fluid diffusivity predicts clinical deterioration in prodromal and early-stage Parkinson’s disease.

Article References:
Xing, Y., Lin, M., Li, J. et al. Perivascular space fluid diffusivity predicts clinical deterioration in prodromal and early-stage Parkinson’s disease. npj Parkinsons Dis. 11, 169 (2025). https://doi.org/10.1038/s41531-025-01036-6

Image Credits: AI Generated